Highest-materiality recent filing
WTW Q1 2026: revenue $2.4B (+8% YoY), adj. diluted EPS $3.72 (+19%), organic growth 3%
Revenue $2.412B (+8% YoY); organic growth 3%; diluted EPS $3.10 (+33%).
WTW Q4 adj. EPS $8.12 (+2%), organic rev +6%; FY adj. EPS $17.08 (+5%)
Q4 revenue $2.94B (organic +6%); adj. EPS $8.12 (+2%); operating margin 34.6%.
WTW completes acquisition of Newfront; expands U.S. middle market & tech capabilities
Completed acquisition of Newfront, a top-40 U.S. broker specializing in tech, fintech, and life sciences.
WTW enters $775M delayed draw term loan to finance Newfront acquisition
Delayed draw term loan facility of $775M, unsecured, matures 3 years from initial draw or 3 years after 2 months post-acquisition.
Willis Towers Watson issues $1B in senior notes to fund Newfront acquisition & refinance debt
Issued $700M 4.550% notes due 2031 and $300M 5.150% notes due 2036; net proceeds ~$990M.
WTW to acquire Newfront for $1.3B to expand U.S. middle-market and tech capabilities
Upfront payment of $1.05B ($900M cash + $150M equity) plus up to $250M contingent consideration; total $1.3B.
WTW reports Q3 2025 adjusted EPS $3.07 (+11% YoY); organic revenue growth 5%
Revenue $2.29B flat YoY (organic +5%); diluted EPS $3.11 vs loss $16.44 prior year.
WTW Q3 adj EPS $3.07 (+11% YoY); organic revenue +5%; margins expand 230 bps
Revenue $2.29B flat YoY as TRANZACT sale offset; organic revenue grew 5%.
WTW Q2 2025: Adj. EPS $2.86 (+20% YoY), organic revenue +5%, margins expand
Revenue $2.26B flat (organic +5%); Diluted EPS $3.32 (+144%), Adjusted EPS $2.86 (+20%).
WTW Q4 adjusted EPS $8.13 (+9%); FY adjusted EPS $16.93 (+17%); revenue up 5% organic
Q4 revenue $3.04B (+4% reported, +5% organic); FY revenue $9.93B (+5% reported and organic).
WTW completes sale of TRANZACT to GTCR and Recognize
Sale closed on Dec 31, 2024; announced Jan 2, 2025.
WTW Q3 adj. EPS $2.93 beats; revenue up 6% organic; FY24 guidance reaffirmed
Revenue $2.29B, up 6% YoY (organic 6%); segments: HWC +4%, R&B +10%.
WTW to sell TRANZACT for $632.4M; expects Q3 impairment charges of $1.6–$2.1B
Sale to GTCR and Recognize at $632.4M subject to adjustments; expected close by end of 2024.
WTW Q2 revenue $2.27B (+5%), adj. EPS $2.55 (+24%); raises 2024 outlook low end
Revenue $2.27B, reported +5%, organic +6%; diluted EPS $1.36 (+55%), adjusted diluted EPS $2.55 (+24%).
WTW Q1 revenue up 4% to $2.34B; adj. EPS $3.29 beats prior year; guidance reaffirmed
Q1 revenue $2.34B (+4% reported, +5% organic); diluted EPS $1.83 (down 3%); adjusted diluted EPS $3.29 (+16% YoY).
WTW Q4 revenue up 7% to $2.9B; adjusted EPS $7.44 (+18% YoY); FY2024 guidance reaffirmed
Q4 revenue $2.91B (+7% reported, +6% organic); FY revenue $9.48B (+7% reported, +8% organic).
WTW Q3 revenue up 11% to $2.2B; adjusted EPS up 2% to $2.24; GAAP EPS down 25%
Revenue $2,166M, +11% reported, +9% organic; HWC +9% organic, R&B +10% organic.
WTW Q2 revenue up 6% but adjusted EPS down 12%; lowers 2024 margin and EPS targets
Revenue $2.16B (+6% YoY, organic +7%); adjusted Diluted EPS $2.05 (down 12%).
Willis North America Inc. issues $750M 5.350% Senior Notes due 2033
Issued $750M aggregate principal of 5.350% Senior Notes due May 15, 2033.
WTW Q1 revenue $2.24B, +8% organic; diluted EPS $1.88, +83% YoY
Revenue $2.24B (+4% reported, +8% organic); diluted EPS $1.88 (+83% from $1.03).
WTW Q4 adjusted EPS $6.33, +12% YoY; organic revenue growth 5%; full year adjusted EPS +16%
Q4 2022 revenue $2.72B (+1% reported, +5% organic); full year revenue $8.87B (-1% reported, +4% organic).
WTW Q3: adj EPS $2.20 (+27%), organic rev +6%, raises cost-savings target
Total rev $1.95B (-1% reported, +6% organic); adj op margin 14.5% (+110 bps).
WTW Q2 GAAP EPS $0.97, adjusted EPS $2.32; raises transformation savings target to $80M+
Total revenue $2.031B, down 3% YoY; organic growth +3%.
WTW Q1 revenue -3% to $2.16B, net income drops 83% to $125M, adj EPS +22% to $2.66
Total revenue $2.16B, down 3% YoY; organic growth 2%.
Willis Towers Watson revamps 2022 incentive plans and CEO Carl Hess's severance
2022 STI program: 66.7% enterprise financial (adjusted net revenue & adjusted operating income), 33.3% individual; payout 50%-200% of target.
WTW Q4 2021 revenue $2.71B (+1%); adj. EPS $5.67 (+9%); full-year free cash flow $1.91B (+23%)
Q4 revenue $2.71B, +1% YoY; organic revenue growth 4% for Q4 and 6% for full year 2021.
Carl Hess named CEO of Willis Towers Watson effective Jan 1, 2022; compensation set at $7.25M LTI
Carl Hess appointed CEO effective Jan 1, 2022; receives $7.25M 2022 LTI award, $1M base salary, 175% STI target.
WTW and AJG amend Willis Re sale agreement; set closing dates and fix exchange rates
Closing Letter Agreement signed December 1, 2021 amends SAPA for Willis Re sale.
Willis Towers Watson sells Willis Re to Gallagher for $3.25B cash plus up to $750M earnout
Sale closed Dec 1, 2021; total upfront cash $3.25B, earnout up to $750M payable in 2025.
Willis Towers Watson appoints four new directors, targets $300M+ cost savings by 2024
New directors: Inga Beale, Fumbi Chima, Michael Hammond, Michelle Swanback; three on Jan 1, Chima on April 1.
The Board has selected Paul Reilly, an independent director of the Board, to become the Non-Executive Chair of the Board effective as of the conclusion of the 2025 AGM, subject to his re-election.
Paul Thomas, the current Non-Executive Chair of the Board of Directors (the “Board”) of Willis Towers Watson Public Limited Company (the “Company”), informed the Board that he intends to retire at the end of his current term and will not stand for reelection at the Company’s 2025 Annual Meeting of Stockholders (“AGM”).
upon the arrival of Lucy Clarke as president, Risk & Broking
Adam Garrard will assume the role of chairman, Risk and Broking
On December 7, 2022, the Board of Directors (the "Board") of Willis Towers Watson (the "Company") appointed Mr. Stephen Chipman, Ms. Jackie Hunt, and Mr. Fredric Tomczyk to the Board, each with a start date effective April 1, 2023.
two current directors, Mr. Brendan O'Neill and Ms. Linda Rabbitt, gave notice to the Company that they will not be standing for re-election at the Company's next Annual General Meeting, to be held in the second quarter of 2023.
On December 7, 2022, the Board of Directors (the "Board") of Willis Towers Watson (the "Company") appointed Mr. Stephen Chipman, Ms. Jackie Hunt, and Mr. Fredric Tomczyk to the Board, each with a start date effective April 1, 2023.
On December 7, 2022, the Board of Directors (the "Board") of Willis Towers Watson (the "Company") appointed Mr. Stephen Chipman, Ms. Jackie Hunt, and Mr. Fredric Tomczyk to the Board, each with a start date effective April 1, 2023.
two current directors, Mr. Brendan O'Neill and Ms. Linda Rabbitt, gave notice to the Company that they will not be standing for re-election at the Company's next Annual General Meeting, to be held in the second quarter of 2023.
On December 28, 2021, each of Anna Catalano, Wendy Lane and Wilhelm Zeller provided notice to Willis Towers Watson Public Limited Company (the “Company”) that they had definitively concluded that they will not be standing for re-election to the Board of Directors (the “Board”) at the 2022 Annual General Meeting of Shareholders (“AGM”).
The Board has also appointed Paul Thomas to serve as the next Non-Executive Chair of the Board, succeeding Victor Ganzi at the conclusion of his term at the 2022 AGM.
On December 28, 2021, each of Anna Catalano, Wendy Lane and Wilhelm Zeller provided notice to Willis Towers Watson Public Limited Company (the “Company”) that they had definitively concluded that they will not be standing for re-election to the Board of Directors (the “Board”) at the 2022 Annual General Meeting of Shareholders (“AGM”).
Max materiality 0.85 · Median 0.62 · Most common event earnings